VIRS - Pacer BioThreat Strategy ETF
| Assets | $4.57M |
| NAV | $30.46 |
| Expense Ratio | 0.70% |
| PE Ratio | 25.09 |
| Beta (5Y) | -0.84 |
| Dividend (ttm) | $0.15 |
| Dividend Yield | 0.48% |
| Ex-Dividend Date | Mar 22, 2021 |
| 1-Year Return | - |
| Trading Day | April 21 |
| Last Price | $30.46 |
| Previous Close | $30.29 |
| Change ($) | 0.17 |
| Change (%) | 0.57% |
| Day's Open | 30.29 |
| Day's Range | 30.28 - 30.46 |
| Day's Volume | 1,124 |
| 52-Week Range | 24.17 - 30.59 |
Fund Description
The investment seeks to track the performance, before fees and expenses, of the LifeSci BioThreat Strategy Index (the "index"). Under normal circumstances, at least 80% of the fund's total assets (exclusive of collateral held from securities lending) will be invested in the component securities of the index. The index is generally composed of U.S.-listed stocks of companies whose products or services help protect against, endure, or recover from biological threats to human health. It is non-diversified.
| Asset Class Equity | Inception Date Jun 24, 2020 |
| Exchange BATS | Ticker Symbol VIRS |
| Index Tracked LifeSci BioThreat Strategy
Index | |
Top 10 Holdings
49.28% of assets| Name | Symbol | Weight |
|---|---|---|
| Home Depot | HD | 5.42% |
| Abbott Laboratories | ABT | 5.23% |
| Johnson & Johnson | JNJ | 5.06% |
| NVIDIA | NVDA | 4.99% |
| Lowe's | LOW | 4.98% |
| Netflix | NFLX | 4.87% |
| Danaher | DHR | 4.76% |
| Thermo Fisher Scientific | TMO | 4.76% |
| Amazon | AMZN | 4.73% |
| Walmart | WMT | 4.49% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Mar 22, 2021 | $0.05936 | Jan 1, 1970 |
| Dec 21, 2020 | $0.03944 | Jan 1, 1970 |
| Sep 21, 2020 | $0.04845 | Jan 1, 1970 |
The first half of 2021 is expected to continue bearing the brunt of the coronavirus outbreak considering the pandemic's renewed resurgence thanks to variants. Thus, a COVID-themed ETF could be a smart p...
The first half of 2021 is expected to continue bearing the brunt of the coronavirus outbreak. Thus, a COVID-themed ETF could be a smart pick.
The rest of 2020 and the beginning of 2021 are expected to continue bearing the brunt of the coronavirus outbreak. Thus, a COVID-themed ETF could be a smart pick.
The remainder of 2020 is expected to continue bearing the brunt of the coronavirus outbreak and therefore, a COVID-19-themed ETF could be a smart pick.
Both companies have reasonable chances of beating earnings estimates with Netflix witnessing positive earnings estimate revisions. On the other hand, Amazon saw negative earnings estimate revision.
It feels like the rest of 2020 will continue to bear the brunt of the coronavirus outbreak and therefore, a COVID-19-themed ETF could be a smart pick.
The news has put the spotlight on some ETFs, which could be the best ways for investors to tap the opportunity arising from the proposed Nvidia deal.
News broke Saturday that semiconductor giant Nvidia (NASDAQ: NVDA) is in talks to acquire Arm Holdings, a UK-based chip designer, from Japan's SoftBank Group for $40 billion.
There are advantages -- and disadvantages -- to some of the newest ETFs on the market.
In the current scenario of the rising work-from-home and online shopping trends, online learning, home entertainment, telemedicine and digital health services are slowly becoming the "new normal."
The Pacer BioThreat Strategy ETF (VIRS) is an outperforming healthcare sector-related exchange traded fund that has benefited from exposure to areas outside of the healthcare solutions category. Over th...
In the current scenario of the rising work-from-home and online shopping trends, online learning, home entertainment, telemedicine and digital health services are slowly becoming the "new normal."
Should You Invest in COVID Themed ETFs?
We highlight three new ETFs that seek to capitalize on coronavirus.
While Netflix beat revenue estimates and reported solid subscriber addition, it missed the earnings estimate and offered weak third-quarter subscriber guidance.
The outperformance for Netflix is expected to continue given that the company has strong chances of beating estimates for the second quarter and witnessed positive earnings estimate revisions.
There are a handful of new ETFs on the market today that are spins on the novel coronavirus, with the VIRS ETF currently as the most diverse.
Overall, the S&P 500 is down 1.6% this year (as of Jul 6, 2020) while the Nasdaq Composite has gained 16.3% in the year-to-date frame. The Dow Jones has suffered the most with 7.9% year-to-date loss.
It was just a week ago that the first exchange-traded fund dedicated to vaccine developers, plenty engaged in the fight against the coronavirus, came to market.